Abstract
Lung cancer including non-small cell lung carcinoma (NSCLC) represents a leading cause of cancer death in Western countries. Yet, understanding its pathobiology to improve early diagnosis and therapeutic strategies is still a major challenge of today's biomedical research. We analyzed a set of differentially regulated genes that were identified in skin cancer by a comprehensive microarray study, for their expression in NSCLC. We found that ferm domain containing protein 3 (FRMD3), a member of the protein 4.1 superfamily, is expressed in normal lung tissue but silenced in 54 out of 58 independent primary NSCLC tumours compared to patient-matched normal lung tissue. FRMD3 overexpression in different epithelial cell lines resulted in a decreased clonogenicity as measured by colony formation assay. Although cell attachment capabilities and cell proliferation rate remained unchanged, this phenotype was most likely owing to induced apoptosis. Our data identify FRMD3 as a novel putative tumour suppressor gene suggesting an important role in the origin and progression of lung cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- AC:
-
adenocarcinoma
- CFA:
-
colony formation assay
- DAL-1:
-
differentially expressed in carcinoma of the lung 1
- FRMD3:
-
ferm domain containing protein 3
- NSCLC:
-
non small cell lung carcinoma
- pSCC:
-
pulmonary squamous cell carcinoma
- sqRT–PCR:
-
semiquantitative RT–PCR
References
Breitenbach U, Tuckermann JP, Gebhardt C, Richter KH, Furstenberger G, Christofori G et al. (2001). Keratinocyte-specific onset of serine protease BSSP expression in experimental carcinogenesis. J Invest Dermatol 117: 634–640.
Charboneau AL, Singh V, Yu T, Newsham IF . (2002). Suppression of growth and increased cellular attachment after expression of DAL-1 in MCF-7 breast cancer cells. Int J Cancer 100: 181–188.
Forgacs E, Zochbauer-Muller S, Olah E, Minna JD . (2001). Molecular genetic abnormalities in the pathogenesis of human lung cancer. Pathol Oncol Res 7: 6–13.
Gerber MA, Bahr SM, Gutmann DH . (2006). Protein 4.1B/differentially expressed in adenocarcinoma of the lung-1 functions as a growth suppressor in meningioma cells by activating Rac1-dependent c-Jun-NH2-kinase signaling. Cancer Res 66: 5295–5303.
Greenlee RT, Murray T, Bolden S, Wingo PA . (2000). Cancer statistics, 2000. CA Cancer J Clin 50: 7–33.
Gutmann DH, Donahoe J, Perry A, Lemke N, Gorse K, Kittiniyom K et al. (2000). Loss of DAL-1, a protein 4.1-related tumor suppressor, is an important early event in the pathogenesis of meningiomas. Hum Mol Genet 9: 1495–1500.
Gutmann DH, Hirbe AC, Huang ZY, Haipek CA . (2001). The protein 4.1 tumor suppressor, DAL-1, impairs cell motility, but regulates proliferation in a cell-type-specific fashion. Neurobiol Dis 8: 266–278.
Hanada T, Takeuchi A, Sondarva G, Chishti AH . (2003). Protein 4.1-mediated membrane targeting of human discs large in epithelial cells. J Biol Chem 278: 34445–34450.
Huang S, Lichtenauer UD, Pack S, Wang C, Kim AC, Lutchman M et al. (2001). Reassignment of the EPB4.1 gene to 1p36 and assessment of its involvement in neuroblastomas. Eur J Clin Invest 31: 907–914.
Hummerich L, Muller R, Hess J, Kokocinski F, Hahn M, Furstenberger G et al. (2006). Identification of novel tumour-associated genes differentially expressed in the process of squamous cell cancer development. Oncogene 25: 111–121.
Jiang W, Newsham IF . (2006). The tumor suppressor DAL-1/4.1B and protein methylation cooperate in inducing apoptosis in MCF-7 breast cancer cells. Mol Cancer 5: 4 [Epub ahead of print].
Kuns R, Kissil JL, Newsham IF, Jacks T, Gutmann DH, Sherman LS . (2005). Protein 4.1B expression is induced in mammary epithelial cells during pregnancy and regulates their proliferation. Oncogene 24: 6502–6515.
Mao X, Seidlitz E, Ghosh K, Murakami Y, Ghosh HP . (2003). The cytoplasmic domain is critical to the tumor suppressor activity of TSLC1 in non-small cell lung cancer. Cancer Res 63: 7979–7985.
Minna JD, Roth JA, Gazdar AF . (2002). Focus on lung cancer. Cancer Cell 1: 49–52.
Ni X, Ji C, Cao G, Cheng H, Guo L, Gu S et al. (2003). Molecular cloning and characterization of the protein 4.1O gene, a novel member of the protein 4.1 family with focal expression in ovary. J Hum Genet 48: 101–106.
Panani AD, Roussous C . (2006). Cytogenetic and molecular aspects of lung cancer. Cancer Lett 239: 1–9.
Perry A, Cai DX, Scheithauer BW, Swanson PE, Lohse CM, Newsham IF et al. (2000). Merlin, DAL-1, and progesterone receptor expression in clinicopathologic subsets of meningioma: a correlative immunohistochemical study of 175 cases. J Neuropathol Exp Neurol 59: 872–879.
Rapp UR, Fensterle J, Albert S, Gotz R . (2003). Raf kinases in lung tumor development. Adv Enzyme Regul 43: 183–195.
Robb VA, Gerber MA, Hart-Mahon EK, Gutmann DH . (2005). Membrane localization of the U2 domain of Protein 4.1B is necessary and sufficient for meningioma growth suppression. Oncogene 24: 1946–1957.
Robb VA, Li W, Gascard P, Perry A, Mohandas N, Gutmann DH . (2003). Identification of a third Protein 4.1 tumor suppressor, Protein 4.1R, in meningioma pathogenesis. Neurobiol Dis 13: 191–202.
Robb VA, Li W, Gutmann DH . (2004). Disruption of 14-3-3 binding does not impair Protein 4.1B growth suppression. Oncogene 23: 3589–3596.
Schlingemann J, Hess J, Wrobel G, Breitenbach U, Gebhardt C, Steinlein P et al. (2003). Profile of gene expression induced by the tumour promotor TPA in murine epithelial cells. Int J Cancer 104: 699–708.
Shaw AT, Kirsch DG, Jacks T . (2005). Future of early detection of lung cancer: the role of mouse models. Clin Cancer Res 11: 4999s–5003s.
Sherman LS, Gutmann DH . (2001). Merlin: hanging tumor suppression on the Rac. Trends Cell Biol 11: 442–444.
Singh V, Miranda TB, Jiang W, Frankel A, Roemer ME, Robb VA et al. (2004). DAL-1/4.1B tumor suppressor interacts with protein arginine N-methyltransferase 3 (PRMT3) and inhibits its ability to methylate substrates in vitro and in vivo. Oncogene 23: 7761–7771.
Sun CX, Robb VA, Gutmann DH . (2002). Protein 4.1 tumor suppressors: getting a FERM grip on growth regulation. J Cell Sci 115: 3991–4000.
Tran YK, Bogler O, Gorse KM, Wieland I, Green MR, Newsham IF . (1999). A novel member of the NF2/ERM/4.1 superfamily with growth suppressing properties in lung cancer. Cancer Res 59: 35–43.
Yageta M, Kuramochi M, Masuda M, Fukami T, Fukuhara H, Maruyama T et al. (2002). Direct association of TSLC1 and DAL-1, two distinct tumor suppressor proteins in lung cancer. Cancer Res 62: 5129–5133.
Acknowledgements
We acknowledge Dr Marina Schorpp-Kistner for helpful discussion about the manuscript and associated work. We thank Dr Irena Crnković-Mertens for help with preparing the RNAs of some of the N/T-samples. NSCLC tissues were obtained according to the ethic votum 270/2001, version 2.0 (23 January 2005).
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc).
Supplementary information
Rights and permissions
About this article
Cite this article
Haase, D., Meister, M., Muley, T. et al. FRMD3, a novel putative tumour suppressor in NSCLC. Oncogene 26, 4464–4468 (2007). https://doi.org/10.1038/sj.onc.1210225
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1210225
Keywords
This article is cited by
-
FRMD3 inhibits the growth and metastasis of breast cancer through the ubiquitination-mediated degradation of vimentin and subsequent impairment of focal adhesion
Cell Death & Disease (2023)
-
Hsa-miR-3651 could serve as a novel predictor for in-breast recurrence via FRMD3
Breast Cancer (2022)
-
High FRMD3 expression is prognostic for worse survival in rectal cancer patients treated with CCRT
International Journal of Clinical Oncology (2021)
-
rs1888747 polymorphism in the FRMD3 gene, gene and protein expression: role in diabetic kidney disease
Diabetology & Metabolic Syndrome (2016)
-
Willin/FRMD6 expression activates the Hippo signaling pathway kinases in mammals and antagonizes oncogenic YAP
Oncogene (2012)